Copenhagen, 2014-12-15 09:45 CET (GLOBE NEWSWIRE) -- Company Announcement
No. 20/2014
Copenhagen, 15 December 2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) announced today that Senior Vice President and Chief Business Officer, Dr. Arvind Hundal, has stepped down to pursue other opportunities outside the company.
Arvind Hundal joined Zealand in 2009 and was nominated to the position of Chief Business Officer in 2011, at which time she also joined the company’s Executive Management team.
In a comment to this announcement, David Solomon, President and CEO of Zealand, said:
“Arvind Hundal has made valuable contributions to building Zealand’s large portfolio of partnership agreements over the past five years. It is to a large extent also thanks to Arvind and the team’s achievements that Zealand today stands with a solid platform from which to move to the next level in its development, and we wish her all the best in her next endeavors.”
***
For further information, please contact:
David Solomon, President and Chief Executive Officer
Tel: +45 22 20 63 00
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences also in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing of Lyxumia® is planned for summer 2015 and of LixiLan as early as end 2015.
Zealand proprietary pipeline includes danegaptide (prevention of ischemic reperfusion injury) and the stable glucagon analogue, ZP4207 (treatment of severe hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
